-
MaxCyte to cut 34% of workforce in restructuring to reach profitability
-
MaxCyte, Inc. (MXCT) Announces Departure of Chief Commercial Officer
-
BTIG Downgrades MaxCyte Inc. (MXCT) to Neutral
-
William Blair Downgrades MaxCyte Inc. (MXCT) to Market Perform
-
MaxCyte, Inc. (MXCT) Misses Q2 EPS by 2c
-
MaxCyte Inc. (MXCT) PT Lowered to $5 at BTIG
-
MaxCyte, Inc. (MXCT) Tops Q1 EPS by 1c
-
MaxCyte Inc. (MXCT) PT Lowered to $9 at Stifel
-
MaxCyte Inc. (MXCT) PT Lowered to $6 at BTIG
-
MaxCyte, Inc. (MXCT) Tops Q4 EPS by 2c
-
MaxCyte, Inc. (MXCT) Tops Q3 EPS by 1c
-
Poseida Therapeutics (PSTX) Appoints Cynthia Collins to its Board
-
TD Cowen Reiterates Buy Rating on MaxCyte Inc. (MXCT)

